Drug Profile
Research programme: cellular energy metabolism-targeted therapeutics - Sumitomo Pharma/BioElectron Technology
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma; Edison Pharmaceuticals
- Developer BioElectron Technology; Sumitomo Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mitochondrial disorders; Neurological disorders